Status:

UNKNOWN

Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)

Lead Sponsor:

Hospital San Vicente Fundación

Collaborating Sponsors:

Clínica León XIII

Grupo de Inmunodeficiencias primarias Universidad de Antioquia

Conditions:

SARS-Cov-2

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Convalescent plasma has been used for over 100 years in the treatment of severe acute respiratory infections of viral origin. There are not pharmacological treatments for the actual outbreak for SARS-...

Detailed Description

Coronavirus infection has been declared by the World Health Organization as a pandemic. In addition to hemodynamic and ventilatory support in the intensive care unit, there is no treatment for COVID-1...

Eligibility Criteria

Inclusion

  • For plasma donors:
  • Over 18 years of age
  • Men or nulliparous women with no history of recent abortions or transfusions SARS-CoV-2 infection by PCR in any sample or serological test with a maximum of 60 days from resolution of symptoms.
  • If donation is done within 14 to 28 days after resolution of symptoms, the patient must have a negative PCR test for SARS-CoV-2. If donation is done after 28 days of resolving symptoms, no negative control test will be required.
  • For plasma recipients:
  • Over 18 years of age
  • SARS-CoV-2 infection confirmed by PCR in any sample
  • Hospitalized in the ICU due to shock or respiratory failure, with less than 24 hours after entering the ICU.

Exclusion

  • For plasma donors:
  • Severe SARS-CoV-2 infections with an ICU requirement or those with asymptomatic infections will not be accepted as donors.
  • Nor will a person who has received convalescent plasma as part of the COVID-19 treatment.
  • For plasma receivers:
  • Serious volume overload or other condition that contraindicates plasma transfusion.
  • History of anaphylaxis or serious adverse reaction to plasma.
  • Previous diagnosis of immunoglobulin A deficiency

Key Trial Info

Start Date :

June 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2021

Estimated Enrollment :

231 Patients enrolled

Trial Details

Trial ID

NCT04391101

Start Date

June 1 2020

End Date

December 1 2021

Last Update

May 20 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital San Vicente Fundacion

Medellín, Antioquia, Colombia